The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Final safety results from ATHENA–MONO (GOG-3020/ENGOT-ov45), a randomized, placebo-controlled, double-blind, phase 3 trial evaluating rucaparib monotherapy as maintenance treatment in patients with newly diagnosed ovarian cancer.
 
David M. O'Malley
Consulting or Advisory Role - Adaptimmune; Agenus; AstraZeneca; Clovis Oncology; Corcept Therapeutics; DualityBio; Eisai; Elevar Therapeutics; GlaxoSmithKline; GOG Foundation; Immunogen; Imvax; Laekna Therapeutics; Merck; Mersana; Novartis; Novocure; Novocure; OncoC4; Onconova Therapeutics; Regeneron; Roche; Seagen; Sutro Biopharma; Umoja Biopharma; Verastem
Research Funding - Abbvie (Inst); Abbvie/Stemcentrx (Inst); Acerta Pharma (Inst); Advaxis (Inst); Ajinomoto (Inst); Ajinomoto (Inst); Amgen (Inst); Arcus Biosciences (Inst); Array BioPharma (Inst); AstraZeneca (Inst); BBI Healthcare (Inst); BeiGene (Inst); Bristol-Myers Squibb (Inst); Cerulean Pharma (Inst); Clovis Oncology (Inst); Deciphera (Inst); Eisai (Inst); EMD Serono (Inst); EMD Serono (Inst); Ergomed (Inst); Exelixis (Inst); Genentech/Roche (Inst); Genmab (Inst); GlaxoSmithKline (Inst); Immunogen (Inst); Immunogen (Inst); Incyte (Inst); Iovance Biotherapeutics (Inst); Janssen Research & Development (Inst); Karyopharm Therapeutics (Inst); Leap Therapeutics (Inst); Ludwig Institute for Cancer Research (Inst); Merck (Inst); Mersana (Inst); Novartis (Inst); NovoCure (Inst); OncoQuest (Inst); Pfizer (Inst); PharmaMar (Inst); Precision Therapeutics (Inst); Regeneron (Inst); Roche (Inst); Sanofi (Inst); SeaGen (Inst); Seagen (Inst); Sumitomo Dainippon Pharma Oncology, Inc. (Inst); Sutro Biopharma (Inst); Tesaro (Inst); TRACON Pharma (Inst); Verastem (Inst)
 
Bradley J. Monk
Leadership - US Oncology
Honoraria - Acrivon Therapeutics; Adaptimmune; Agenus; Akeso Biopharma; Amgen; Aravive; AstraZeneca; Bayer; Clovis Oncology; Eisai; Elevar Therapeutics; EMD Serono/Merck; Genmab/Seattle Genetics; GOG Foundation; Gradalis; HenRui; ImmunoGen; Iovance Biotherapeutics; Karyopharm Therapeutics; Laekna Health Care; Merck; Mersana; Myriad Pharmaceuticals; Novartis; Novocure; OncoC4; Panavance Therapeutics; Pfizer; Pieris Pharmaceuticals; Puma Biotechnology; Regeneron; Roche/Genentech; Sorrento Therapeutics; TESARO/GSK; US Oncology; Vascular Biogenics; Verastem; Zentalis
Consulting or Advisory Role - Adaptimmune; Agenus; Akeso Biopharma; Amgen; Aravive; AstraZeneca; Bayer; Clovis Oncology; Eisai; Elevar Therapeutics; EMD Serono/Merck; Genmab/Seattle Genetics; GOG Foundation; Gradalis; Gradalis; HenRui; ImmunoGen; Iovance Biotherapeutics; Karyopharm Therapeutics; Laekna Health Care; Merck; Mersana; Myriad Pharmaceuticals; Novartis; Novocure; OncoC4; Panavance Therapeutics; Pfizer; Pieris Pharmaceuticals; Puma Biotechnology; Regeneron; Roche/Genentech; Sorrento Therapeutics; TESARO/GSK; US Oncology; Vascular Biogenics; Verastem; Zentalis
Speakers' Bureau - AstraZeneca; Clovis Oncology; Eisai; Merck; Roche/Genentech; TESARO/GSK
Research Funding - Advaxis (Inst); Amgen (Inst); Array BioPharma (Inst); AstraZeneca (Inst); Genentech (Inst); Immunogen (Inst); Janssen (Inst); Lilly (Inst); Morphotek (Inst); Novartis (Inst); Nucana (Inst); Pfizer (Inst); Regeneron (Inst); Tesaro (Inst)
 
Myong Cheol Lim
Consulting or Advisory Role - AstraZeneca; Boryung; CKD Pharm; Genexine; GI Innovation; Hospicare; Takeda
Research Funding - Abbvie (Inst); Amgen (Inst); Astellas Pharma; AstraZeneca (Inst); BeiGene (Inst); Cellid (Inst); CKD pharm (Inst); Clovis Oncology (Inst); Eisai (Inst); Genexine (Inst); GlaxoSmithKline (Inst); Incyte (Inst); Incyte (Inst); Merck (Inst); MSD (Inst); OncoQuest (Inst); Pfizer (Inst); Roche (Inst)
 
Jose Fuentes Pradera
Consulting or Advisory Role - MSD Oncology; Roche/Genentech
Speakers' Bureau - AstraZeneca; Bristol-Myers Squibb/Medarex; Pfizer; Sanofi; Takeda
Research Funding - BeiGene (Inst); Daiichi Sankyo/Astra Zeneca (Inst); Gilead Sciences (Inst); MSD Oncology (Inst); Roche/Genentech (Inst)
Other Relationship - Pfizer
 
Joseph Buscema
Employment - Arizona Oncology
Leadership - Arizona Oncology
Stock and Other Ownership Interests - McKesson
Honoraria - Caris Life Sciences
Consulting or Advisory Role - Caris Life Sciences; GlaxoSmithKline
 
Michelle K. Wilson
Research Funding - Foundation Medicine (Inst)
 
Rocco De Vivo
No Relationships to Disclose
 
Thomas J. Herzog
Leadership - GOG Foundation
Consulting or Advisory Role - Aadi; AstraZeneca; Caris MPI; Clovis Oncology; Corcept Therapeutics; Eisai; Epsilogen; GlaxoSmithKline; Johnson & Johnson; Merck; Mersana; Seagen
 
Flora Zagouri
Honoraria - AstraZeneca; Daiichi Sankyo Europe GmbH; Genesis Pharma; Gilead Sciences; Lilly; Merck; MSD; Novartis; Pfizer Hellas; Roche
Consulting or Advisory Role - AstraZeneca; Daiichi Sankyo Europe GmbH; Genesis Pharma; Gilead Sciences; Lilly; Merck; MSD Oncology; Novartis; Pfizer Hellas; Roche
Travel, Accommodations, Expenses - AstraZeneca; Daiichi Sankyo Europe GmbH; Genesis Pharma; Gilead Sciences; Lilly; Merck; MSD Oncology; Novartis; Pfizer Hellas; Roche
 
Amit M. Oza
Consulting or Advisory Role - AstraZeneca; MorphoSys
Research Funding - AstraZeneca (Inst); GlaxoSmithKline (Inst); Merck (Inst)
(OPTIONAL) Uncompensated Relationships - Ozmosis Research
 
Olga N. Mikheeva
No Relationships to Disclose
 
John Paul Diaz
Speakers' Bureau - AstraZeneca
Research Funding - Merck (Inst)
 
Alla Sergeevna Lisyanskaya
No Relationships to Disclose
 
Robert Morris
Honoraria - AstraZeneca; Clovis Oncology; GlaxoSmithKline
Speakers' Bureau - AstraZeneca; Clovis Oncology; GlaxoSmithKline
Research Funding - Athena Trial (Inst); Clovis Oncology (Inst)
 
Ilan Bruchim
No Relationships to Disclose
 
Marcia Craib
Employment - Clovis Oncology; Pharma and
Stock and Other Ownership Interests - Clovis Oncology
 
Christy Connor
Employment - Clovis Oncology; Pharmaand
Stock and Other Ownership Interests - Clovis Oncology
 
Danny Shih
Employment - Clovis Oncology; pharmaand
Stock and Other Ownership Interests - Bristol-Myers Squibb
Travel, Accommodations, Expenses - Clovis Oncology; pharmanad
 
Keiichi Fujiwara
Honoraria - Daiichi Sankyo; Eisai; Genmab; Takeda
Consulting or Advisory Role - Eisai; Genmab; MSD; Seagen; Taiho Pharmaceutical; Takeda
Research Funding - AstraZeneca (Inst); Genmab (Inst); MSD (Inst); Regeneron (Inst); Seagen (Inst)
Travel, Accommodations, Expenses - Genmab
 
Rebecca Kristeleit
Honoraria - AstraZeneca; Basilea; Celcuity; Clovis Oncology; Duke St Bio; Eisai; Leucid Bio; MSD Oncology; Pharma and; Prokarium; Seattle Genetics/Astellas; Shattuck Labs; Tubulis GmbH
Speakers' Bureau - AstraZeneca; Eisai; GlaxoSmithKline; MSD
Research Funding - Incyte